公开(公告)号：US11919910B2

公开(公告)日：2024-03-05

申请号：US17983474

申请日：2022-11-09

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Guoqiang Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Matthew C. Rhodes ,  Yat Sun Or

IPC分类号： C07D487/10 ,  A61P31/14

CPC分类号： C07D487/10 ,  A61P31/14

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11834436B2

公开(公告)日：2023-12-05

申请号：US17228815

申请日：2021-04-13

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC分类号： C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC分类号： C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20230331734A1

公开(公告)日：2023-10-19

申请号：US18130641

申请日：2023-04-04

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC分类号： C07D487/10

CPC分类号： C07D487/10

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230143250A1

公开(公告)日：2023-05-11

申请号：US17891436

申请日：2022-08-19

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  Jun Ma ,  Brett Granger ,  Jiang Long ,  Bin Wang ,  Sourav Ghorai ,  Jing He ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Yat Sun Or

IPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

CPC分类号： C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

摘要： The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20230122228A1

公开(公告)日：2023-04-20

申请号：US17720603

申请日：2022-04-14

申请人： Enanta Pharmaceuticals, Inc.

发明人： Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Matthew C. Rhodes ,  Joseph D. Panarese ,  Samuel Bartlett ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xiaowen Peng ,  Guoqiang Wang ,  Yat Sun Or

IPC分类号： C07D487/10 ,  A61P31/14 ,  A61P11/00 ,  A61K9/00

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220356167A1

公开(公告)日：2022-11-10

申请号：US17197399

申请日：2021-03-10

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC分类号： C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US11345699B2

公开(公告)日：2022-05-31

申请号：US16688429

申请日：2019-11-19

申请人： Enanta Pharmaceuticals, Inc.

发明人： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC分类号： C07D471/04 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20220119366A1

公开(公告)日：2022-04-21

申请号：US17228815

申请日：2021-04-13

申请人： ENANTA PHARMACEUTICALS, INC.

发明人： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC分类号： C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20210238188A1

公开(公告)日：2021-08-05

申请号：US17155159

申请日：2021-01-22

申请人： Enanta Pharmaceuticals, Inc.

发明人： Yong He ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jiang Long ,  Yat Sun Or

IPC分类号： C07D491/048 ,  A61K45/06

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10988458B2

公开(公告)日：2021-04-27

申请号：US16866778

申请日：2020-05-05

申请人： Enanta Pharmaceuticals, Inc.

发明人： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/12

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).